Zenas BioPharma (NASDAQ:ZBIO) Stock Rating Lowered by Zacks Research

Zenas BioPharma (NASDAQ:ZBIO) was downgraded by Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Other equities research analysts have also recently issued research reports about the stock. Citigroup lowered their price target on shares of Zenas BioPharma from $43.00 to $41.00 and set a “buy” rating for the company in a research report on Tuesday. Guggenheim raised their price objective on shares of Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zenas BioPharma in a report on Monday, December 29th. Morgan Stanley upped their target price on shares of Zenas BioPharma from $19.00 to $21.00 and gave the company an “equal weight” rating in a research report on Tuesday. Finally, HC Wainwright reissued a “buy” rating and issued a $44.00 price target on shares of Zenas BioPharma in a research note on Tuesday. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $44.14.

Zenas BioPharma Price Performance

Zenas BioPharma stock opened at $23.03 on Tuesday. The business’s 50-day simple moving average is $22.91 and its 200 day simple moving average is $27.15. The company has a quick ratio of 5.66, a current ratio of 5.61 and a debt-to-equity ratio of 0.32. The stock has a market cap of $1.32 billion, a price-to-earnings ratio of -2.95 and a beta of -1.94. Zenas BioPharma has a 12-month low of $6.11 and a 12-month high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last announced its quarterly earnings data on Monday, March 16th. The company reported ($4.54) earnings per share for the quarter, missing the consensus estimate of ($1.22) by ($3.32).

Insider Activity

In other news, Director Hongbo Lu purchased 25,985 shares of the business’s stock in a transaction that occurred on Wednesday, February 11th. The shares were acquired at an average cost of $22.50 per share, for a total transaction of $584,662.50. Following the transaction, the director directly owned 347,968 shares of the company’s stock, valued at approximately $7,829,280. The trade was a 8.07% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, CEO Leon O. Moulder, Jr. acquired 57,000 shares of Zenas BioPharma stock in a transaction that occurred on Monday, February 2nd. The shares were purchased at an average cost of $17.96 per share, for a total transaction of $1,023,720.00. Following the purchase, the chief executive officer directly owned 423,155 shares in the company, valued at $7,599,863.80. The trade was a 15.57% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 202,845 shares of company stock valued at $3,747,185 in the last ninety days. 16.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Zenas BioPharma

Hedge funds have recently bought and sold shares of the company. PNC Financial Services Group Inc. boosted its position in shares of Zenas BioPharma by 41.2% during the second quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company’s stock worth $89,000 after purchasing an additional 2,679 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Zenas BioPharma by 4.6% in the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock valued at $3,621,000 after buying an additional 16,461 shares in the last quarter. Intech Investment Management LLC raised its stake in Zenas BioPharma by 13.9% during the 2nd quarter. Intech Investment Management LLC now owns 13,206 shares of the company’s stock worth $128,000 after buying an additional 1,607 shares during the period. Rhumbline Advisers raised its stake in Zenas BioPharma by 71.3% during the 2nd quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock worth $191,000 after buying an additional 8,207 shares during the period. Finally, Federated Hermes Inc. lifted its holdings in Zenas BioPharma by 60.8% during the second quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock worth $18,041,000 after acquiring an additional 703,838 shares in the last quarter.

Key Stories Impacting Zenas BioPharma

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: Company says funding supports continued development of obexelimab — a key clinical program that underpins long‑term value, which helps stabilize investor confidence. Zenas BioPharma Funding Supports Obexelimab Plans
• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating and kept a $44 price target, signaling strong upside from some sell‑side analysts and supporting bullish expectations. HC Wainwright Rating
• Neutral Sentiment: Citigroup trimmed its price target from $43 to $41 but maintained a “buy” rating — a modest downgrade to upside assumptions but not a change in overall endorsement. Citigroup Price Target Cut
• Neutral Sentiment: Morgan Stanley raised its target to $21 and kept an “equal weight”/Hold stance, reflecting a balanced near‑term view that recognizes pipeline potential but flags commercial and leverage uncertainties. Morgan Stanley / TipRanks Note
• Negative Sentiment: Quarterly results missed materially — Zenas reported EPS of ($4.54) vs. consensus of ($1.22). The magnitude of the miss increases short‑term downside risk and raises questions about near‑term cash burn and execution. Quarterly Earnings Press Release
• Negative Sentiment: New disclosure of an IPO‑related securities class action introduces additional financial and operational risk, which can pressure the stock while litigation remains unresolved. IPO-Related Class Action

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.